Double-blind, randomised, six-condition crossover study (n=18) testing MDMA 75 mg with ketanserin 50 mg, pindolol 20 mg, and placebo to probe 5-HT2 and 5-HT1A contributions to MDMA-induced memory impairment and impulsivity in experienced MDMA users.
Randomised, double-blind, double-dummy crossover in experienced MDMA users comparing six treatment conditions: MDMA 75 mg alone, MDMA+ketanserin 50 mg, MDMA+pindolol 20 mg, ketanserin alone, pindolol alone, and placebo.
Primary outcomes are neurocognitive measures of memory and impulse control assessed at Tmax; interventions synchronise Tmax using double-dummy administration.
Six-condition double-blind crossover comparing MDMA 75 mg with ketanserin 50 mg, pindolol 20 mg, and placebo in various combinations (double-dummy).
MDMA 75 mg as 25 ml solution in bitter orange peel syrup
Ketanserin 50 mg capsule (5-HT2 antagonist); double-dummy
Pindolol 20 mg capsule (5-HT1A/adrenergic agent); double-dummy
Matching placebo (double-dummy)